NMRA: Neumora Therapeutics, Inc. Company Short-Term Debt

NMRA (Neumora Therapeutics Inc) - company brandmark

Neumora Therapeutics (NMRA) is implementing energy-saving technologies in its laboratories and processing hazardous chemicals in accordance with ESG standards. Due to the clinical trial stage of its drugs, Neumora Therapeutics (NMRA) cannot scale profits, and testing costs are leading to losses. This historical price chart demonstrates the asset's dynamics, where the specific short-term debt indicator equals 0.01. The business specializes in creating innovative medical products for the therapy of nervous system disorders.

NMRA neumoratx.com Company Short-Term Indebtedness (02/21/2024 - 10/31/2026)

Summary analytical data breakdowns for Neumora Corp (NMRA)

- current quotes and average value forecast:
Price Chart Neumora Therapeutics, Inc.|NMRA - Fair Value Consensus
- market capitalization information:
Market Value Neumora Therapeutics, Inc.|NMRA - Total Enterprise Value
- shareholders' equity book value data:
Net Assets per Single Share Neumora Therapeutics|NMRA - Accounting Capitalization|Market Capitalization to Book Value Ratio neumoratx.com|NMRA - Company Assets
- debt and liquidity details:
Total Debt to Equity Ratio Neumora Therapeutics|NMRA - Long-Term Debt to Capital|Short-Term Debt to Equity Neumora Therapeutics|NMRA - Company Total Debt|Debt to Book Capitalization Ratio Neumora Therapeutics, Inc.|NMRA - Long-Term Debt|Company Short-Term Debt Neumora Therapeutics|Quick Ratio neumoratx.com
- earnings and multiples data:
NMRA - Net Profit
Initial company analysis:NMRA - Neumora Therapeutics, Inc.
Flagship merchandise of Neumora Therapeutics

Neumora Therapeutics (NMRA) invests in clinical trials for CNS drugs without possessing current pricing power. The trend in liabilities under one year digitizes research operating expenses and current liquidity. This metric measures the volume of short-term borrowed capital, which is critical for preventing cash flow gaps. Rising debt signals a search for resources to overcome regulatory barriers. Analyzing short-term loan levels allows for an assessment of the company's financial stability.

Main competitors

BIIB - Company Short-Term Debt|Company Short-Term Loans and Borrowings NBIX (Neurocrine)|Regencell (RGC) - Company Short-Term Debt|Short-Term Debt Axsome Corp (AXSM)|Company Short-Term Debt ACADIA Pharmaceuticals|Company Short-Term Indebtedness XENE (xenon-pharma.com)|Company Short-Term Debts VKTX|SUPN - Short-Term Debt|Catalyst Pharmaceuticals Inc - Company Current Liabilities|Company Short-Term Debts Denali Corp DNLI|HRMY - Company Short-Term Debt|biohavenpharma.com (BHVN) - Company Current Liabilities|Amylyx Pharmaceuticals, Inc. (AMLX) - Company Short-Term Debt|Short-Term Debt Trevi Therapeutics Inc (TRVI)|Company Short-Term Debt Praxis Medicines|AVXL: Company Short-Term Loans and Borrowings|Company Short-Term Debts CBLL|Company Short-Term Debts Prothena Corporation plc (PRTA)|Alector - Company Current Liabilities|Company Short-Term Loans and Borrowings ANNX|OMER: Company Current Liabilities|Neurogene Therapeutics - Amount of Current Liabilities|ACIU: Company Short-Term Debts|voyagertherapeutics.com - Company Short-Term Loans and Borrowings|SCLX (Scilex) - Company Short-Term Debts|Short-Term Debt Tevogen Bio Holdings Inc. TVGN|Company Short-Term Debt Alpha Cognition (ACOG)|CGTX (cogrx.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debts IKT (Inhibikase Therapeutics)|Company Short-Term Debts cassavasciences.com SAVA|ASRT - Company Short-Term Debt|Current Liabilities COYA|VTGN: Company Short-Term Debts|Short-Term Debt Ovid Therapeutics (OVID)|Company Current Liabilities ABOS|Company Short-Term Debts cervomed.com|Company Current Liabilities ATHE (Alterity Therapeutics)|Amount of Current Liabilities CLNN|Company Short-Term Debts PEPG (PepGen)|Short-Term Debt Volume jupiterneurosciences.com (JUNS)|Relmada Therapeutics - Company Short-Term Debts|annovisbio.com (ANVS) - Company Current Liabilities|gracetx.com (GRCE) - Company Short-Term Debt|AIFF - Short-Term Debt Volume|Company Short-Term Debt ANEW Medical|Company Short-Term Indebtedness NRSN (NeuroSense Therapeutics, Ltd.)|Company Short-Term Debt Reviva Pharmaceuticals (RVPH)|Company Current Liabilities metaviatx.com MTVA|Company Short-Term Debt NeurAxis NRXS|Company Short-Term Loans and Borrowings HSDT|Passage Bio Corp - Company Short-Term Debts|NEUP - Company Short-Term Debts|Minerva Neurosciences (NERV) - Company Short-Term Debt|Company Short-Term Indebtedness ATHA|ADXN (Addex Therapeutics Ltd) - Company Short-Term Debts|Short-Term Debt Alzamend ALZN|Company Current Liabilities CYCN (Cyclerion Therapeutics)|Company Short-Term Debts protagenic.com (PTIX)|Company Short-Term Debt Pasithea Therapeutics Corp. KTTA|Company Short-Term Loans and Borrowings CRGT|ATXI - Company Short-Term Debt|Short-Term Debt Brainstorm Cell Therapeutics Inc.|Cara Therapeutics, Inc (CARA) - Company Short-Term Debt|Company Short-Term Indebtedness CHRO|ELYM (Eliem Therapeutics, Inc.) - Company Short-Term Debts|Short-Term Debt Intra-Cellular ITCI|Company Current Liabilities LBPH (Longboard Pharmaceuticals, Inc.)|Company Short-Term Debts Marinus Pharmaceuticals Inc (MRNS)|Company Short-Term Debt NKGen NKGN|NRBO - Company Current Liabilities|SAGE - Company Short-Term Debt|Short-Term Debt synaptogen.com|Trevena (TRVN) - Company Short-Term Debt|Vigil Neuroscience, Inc. - Company Short-Term Loans and Borrowings|WENA (Anew Medical, Inc.) - Company Short-Term Debts|Company Short-Term Debts Cerevel Corp